3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Endometrial Neoplasms
2
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Menstruation Disturbances
1
Leiomyoma
1
Endometriosis
1
Adenomyosis
1
Interventions
Bevacizumab
19
Paclitaxel
16
Carboplatin
12
pembrolizumab
11
liposomal doxorubicin
10
Cyclophosphamide
9
Specimen Handling
8
Gemcitabine
8
olaparib
7
fludarabine
7
Topotecan
7
Magnetic Resonance Spectroscopy
7
Taxes
5
Immunoglobulin G
5
Fulvestrant
5
Disulfides
5
niraparib
4
Oxaliplatin
4
Nivolumab
4
Biopsy
4
trastuzumab deruxtecan
3
palbociclib
3
mirvetuximab soravtansine
3
aldesleukin
3
Leucovorin
3
Fluorouracil
3
1-dodecylpyridoxal
3
ulixertinib
2
nilotinib
2
ipatasertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Hysterectomy
×
30 days
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled